Cholinesterase Depression in an Orchard Worker: Carbamate, Organophosphate, or Both?
A 38-year-old orchard worker is brought in 3 hours after spraying insecticide without PPE, with miosis, salivation, bronchorrhea, vomiting, bradycardia of 46, and muscle fasciculations. He improves after three 2 mg IV doses of atropine. Initial samples: erythrocyte acetylcholinesterase 27% and plasma butyrylcholinesterase 12% of the laboratory's reference means. At 30 hours he is clinically stable and off atropine; repeat erythrocyte AChE is 41% of the reference mean. The product label in his truck lists methomyl (a carbamate), but a co-worker says an unlabeled container was also used. There are no pre-exposure baseline cholinesterase values for this crew, and the laboratory reports results only as percent of a population mean.
1. Can the serial enzyme results distinguish a carbamate from an organophosphate? Lay out what the numbers do and do not support.
Read the worked answer
What the numbers support. Carbamylated AChE hydrolyses spontaneously, so erythrocyte activity typically returns toward baseline within roughly 24-72 hours, whereas a phosphorylated enzyme recovers only through synthesis of new red cells (on the order of 1-2% per day). A rise from 27% to 41% of reference in about 30 hours is far too fast for red-cell turnover. That trajectory is strong circumstantial evidence for a carbamate - or for a dimethyl organophosphate with rapid spontaneous reactivation - and argues against a typical diethyl OP such as chlorpyrifos or parathion.
What they do not support.
- No baseline: percent-of-population-mean ignores the 20-30% interindividual spread in normal activity, so a single value can misclassify a person with genetically low or high baseline.
- Plasma BChE is more sensitive but also depressed by liver disease, pregnancy, and some drugs; it is not specific.
- Mixed or unlabeled product: both a carbamate and an OP could have been used; the label in the truck proves nothing about the second container.
- The 41% value was measured during ongoing clinical recovery; atropine effect does not inform enzyme status.
Judgment: treat as carbamate-compatible but do not close the investigation - obtain the container, review the re-entry interval and PPE, and repeat AChE at 7 and 14 days to confirm full return to a stable personal baseline; simultaneously establish baselines for the whole crew.
2. Would an oxime have been indicated? And were the atropine doses adequate?
Read the worked answer
Oxime. Pralidoxime reactivates the phosphorylated enzyme only before 'aging' (dealkylation) makes reactivation impossible; the aging half-life is agent-specific (hours for some dimethyl OPs, days for others). For a carbamate, reactivation is unnecessary because carbamylation reverses spontaneously, and oximes are conventionally not recommended - they offer no benefit and, in theory, some oxime-carbamate complexes are themselves anticholinesterases. Because the agent was uncertain, giving an oxime early would have been defensible if an OP was plausible; the serial recovery data now argue against continuing it. The teaching point is that the decision is time-critical and made on suspicion, not on a definitive assay.
Atropine adequacy. Atropine antagonises muscarinic effects only; it does nothing for the nicotinic fasciculations or the neuromuscular junction. Titration should target drying of pulmonary secretions and resolution of bronchorrhea, not heart rate alone. Three 2 mg boluses with clinical improvement and no requirement for an infusion is a modest total dose; if secretions had persisted, doubling the bolus and starting an infusion would have been correct. Bradycardia of 46 with bronchorrhea is a life-threatening combination and should have driven aggressive dosing. Benzodiazepines are the correct adjunct for fasciculations and seizures.
3. What must be monitored over the next several days, and what should be recommended for the rest of the crew?
Read the worked answer
Intermediate syndrome. Onset typically 24-96 hours after the cholinergic crisis resolves: weakness of proximal limb, neck flexor, and bulbar/respiratory muscles, with preserved consciousness and no fasciculations. It is a neuromuscular junction failure requiring ventilatory monitoring; a patient who is 'better' at 30 hours is precisely the one at risk. Keep under observation with respiratory monitoring through at least 96 hours and a low threshold for spirometry/negative inspiratory force.
Delayed neuropathy. Organophosphate-induced delayed polyneuropathy appears 1-3 weeks later as distal sensorimotor weakness; carbamates are not generally associated with it. A neurological review at 2-4 weeks is appropriate given the uncertain agent.
Crew recommendations:
- Establish pre-exposure (or at minimum inter-season) baseline erythrocyte AChE for every applicator, so future results can be compared to the individual rather than a population mean.
- Enforce PPE and re-entry intervals; review the unlabeled container as a regulatory and workplace-safety issue.
- Nothing in this presentation justifies treating the man as 'sensitised'; the risk to the crew is exposure-based, not individual susceptibility, and the programme should be built around engineering controls, hygiene, and periodic biological monitoring.